📋 Key Information Summary
- Colorectal cancer (CRC) is the second most common cancer in Australia; the National Bowel Cancer Screening Program (NBCSP) provides free faecal immunochemical test (FIT) kits every 2 years to eligible Australians aged 50–74.
- Average-risk individuals should commence structured screening at age 50 with biennial FIT via the NBCSP; emerging guidelines (USPSTF 2021, ACS) support initiating discussion from age 45.
- Increased-risk groups — first-degree relative (FDR) with CRC, hereditary syndromes (Lynch, FAP), inflammatory bowel disease (IBD), prior adenomas — require earlier and more intensive surveillance with colonoscopy.
- FIT is the recommended primary screening modality for average-risk populations due to its sensitivity, non-invasiveness, and cost-effectiveness; a positive FIT mandates diagnostic colonoscopy.
- Colonoscopy remains the gold-standard diagnostic and therapeutic investigation; it enables polypectomy and histological assessment but carries procedural risk (~1:1000 perforation).
- Flexible sigmoidoscopy (once-off around age 55) has an evidence base from landmark RCTs but is less commonly used in Australia than FIT-based programmes.
- Stool DNA (e.g., Cologuard®) is not currently funded by the PBS or MBS in Australia and is not part of the NBCSP; it may be discussed in select clinical scenarios.
- Primary care clinicians are pivotal: opportunistic screening discussions, ensuring NBCSP participation, recognising red-flag symptoms (PR bleeding, iron deficiency anaemia, change in bowel habit), and timely referral.
- All patients with a positive non-invasive screening test must proceed to diagnostic colonoscopy — this is not optional and should occur within 30 days ideally.
- Aboriginal and Torres Strait Islander peoples experience higher CRC incidence and mortality with later-stage diagnosis; culturally safe engagement and addressing barriers to screening are essential.
- Post-polypectomy surveillance intervals follow the 2020 Colorectal Cancer Screening Guidelines: low-risk adenoma → repeat colonoscopy in 5 years; high-risk adenoma → repeat colonoscopy in 3 years.
- Iron deficiency anaemia in any adult, particularly men and postmenopausal women, warrants investigation to exclude CRC regardless of age.
Introduction & Australian Epidemiology
Colorectal cancer (CRC) — encompassing cancers of the colon, rectum, and anus — is a leading cause of cancer-related morbidity and mortality in Australia. The adenoma-carcinoma sequence provides a prolonged window of opportunity during which precursor polyps can be detected and removed, making CRC one of the most screen-preventable malignancies.
According to the Australian Institute of Health and Welfare (AIHW), CRC is the second most commonly diagnosed cancer in both men and women in Australia, with an estimated 15,500 new cases diagnosed annually. It remains the second leading cause of cancer death, responsible for approximately 5,300 deaths per year. The five-year relative survival rate is approximately 70%, but this varies markedly by stage at diagnosis — exceeding 90% for localised disease but falling below 15% for distant metastatic disease.
The Australian Government established the National Bowel Cancer Screening Program (NBCSP) in 2006, which has been progressively expanded. Since 2020, all Australians aged 50–74 receive a free immunochemical faecal occult blood test (iFIT/FIT) kit by mail every two years. Participation rates, however, remain suboptimal at approximately 44% nationally, with lower rates among men, those in lower socioeconomic areas, and Aboriginal and Torres Strait Islander peoples.
Opportunity for early detection: CRC typically develops over 10–15 years from normal mucosa through adenomatous polyp to invasive carcinoma. Screening during this window can prevent cancer entirely through polypectomy or detect it at an early, curable stage.
| Statistic | Value | Source |
|---|---|---|
| New cases per year (est.) | ~15,500 | AIHW 2023 |
| Deaths per year (est.) | ~5,300 | AIHW 2023 |
| 5-year survival (all stages) | ~70% | AIHW Cancer Data |
| NBCSP participation rate | ~44% | AIHW NBCSP Report 2023 |
| NBCSP target age range | 50–74 years | Australian Government DoH |
| Screening interval | Every 2 years | NBCSP |
Risk Stratification & Screening Modalities
Risk stratification is the foundation of an effective CRC screening strategy. Individuals are categorised into average risk, moderately increased risk, and high risk based on personal and family history, with each category dictating the recommended screening modality, starting age, and surveillance interval.
Risk Categories
Average Risk
No Significant Risk Factors
No personal history of CRC, adenomas, or IBD; no family history of CRC; no hereditary syndrome. Age 50–74, asymptomatic.
Modality: NBCSP FIT every 2 years
Moderately Increased Risk
1 FDR with CRC (<55 yrs) or 2 FDRs any age
One first-degree relative diagnosed with CRC before age 55, or two or more first-degree relatives with CRC at any age. Prior history of adenomatous polyps.
Modality: Colonoscopy starting age 40 (or 10 yrs before youngest FDR diagnosis), every 5 years
High Risk
Hereditary Syndromes & IBD
Lynch syndrome (HNPCC), familial adenomatous polyposis (FAP), MYH-associated polyposis (MAP), long-standing ulcerative colitis or Crohn's colitis (>8 yrs extensive disease).
Modality: Surveillance colonoscopy per specialist protocol (see below)
Screening Modalities
| Modality | Sensitivity (CRC) | Specificity | Interval | Australian Availability | Best For |
|---|---|---|---|---|---|
| FIT (Faecal Immunochemical Test) | ~74% (single round); >90% programme sensitivity | ~95% | Every 2 years | NBCSP (free); MBS item 66766 | Average risk, population screening |
| Colonoscopy | ~95% | ~90% | Every 5–10 years (risk-dependent) | MBS item 32222 (colonoscopy); all states | Positive FIT, high risk, surveillance |
| Flexible Sigmoidoscopy | ~70–75% (distal CRC) | ~95% | Once-off (age 55) or every 10 yrs | Available; MBS item 32218 | Average risk (distal colon assessment) |
| Stool DNA / Multitarget Stool DNA | ~92% | ~87% | Every 3 years | Not PBS/MBS funded; available privately | Select cases; not first-line in Australia |
| CT Colonography (Virtual Colonoscopy) | ~90% (>10 mm polyps) | ~86% | Every 5 years | Available; MBS item 57721 (specialist request only) | Patients unable to undergo colonoscopy |
Modality Details
Faecal Immunochemical Test (FIT)
The FIT detects human haemoglobin in stool using antibody-based immunoassay technology. Unlike older guaiac-based faecal occult blood tests (gFOBT), FIT is specific for human globin (not affected by dietary peroxidases) and has superior sensitivity for CRC and advanced adenomas. The NBCSP uses a quantitative FIT with a cut-off of 100 ng/mL buffer (~20 µg Hb/g faeces). A single FIT sample is sufficient for the NBCSP kit.
FIT limitations: FIT has reduced sensitivity for proximal (right-sided) colon cancers and sessile serrated lesions. Repeated biennial testing improves programme-level sensitivity through cumulative detection. FIT does not detect adenomas that are not bleeding at the time of testing.
Colonoscopy
Colonoscopy is the most sensitive and specific test for CRC detection and enables simultaneous biopsy and polypectomy. It requires full bowel preparation, sedation (typically propofol-based monitored anaesthesia care in Australia), and carries a procedural perforation risk of approximately 1 in 1,000 and a significant bleeding risk of 1 in 200 (higher with polypectomy). Adequate bowel preparation and caecal intubation rates (>95%) are quality benchmarks per Gastroenterological Society of Australia (GESA) standards.
Flexible Sigmoidoscopy
Flexible sigmoidoscopy examines the rectum and sigmoid/descending colon to approximately 60 cm. The UK Flexible Sigmoidoscopy Screening Trial demonstrated a 33% reduction in CRC incidence and 43% reduction in CRC mortality with a single screen at age 55–64. In Australia, it is less commonly used as a primary screening tool but remains valuable when colonoscopy is contraindicated or as part of diagnostic workup.
Stool DNA (Multitarget Stool DNA)
Multitarget stool DNA testing (e.g., Cologuard®, combining methylated DNA markers and FIT) has higher single-round sensitivity for CRC (~92%) than FIT alone (~74%), but at the cost of lower specificity (~87% vs ~95%). This test is not currently funded by the PBS or MBS in Australia and is not part of the NBCSP. It may be considered in specific clinical scenarios where colonoscopy is declined or contraindicated, but clinicians should counsel regarding the higher false-positive rate.
Recommended Approach by Risk Level
| Risk Level | First-Line Screening | Start Age | Interval | Alternative / Adjunct |
|---|---|---|---|---|
| Average | FIT (NBCSP) | 50 years | Every 2 years | Flexible sigmoidoscopy once-off at 55; discuss from age 45 per emerging guidance |
| 1 FDR CRC ≥55 yrs | FIT (NBCSP) acceptable | 50 years (or 10 yrs before FDR dx) | Every 2 years | Consider colonoscopy discussion |
| 1 FDR CRC <55 yrs or ≥2 FDRs | Colonoscopy | 40 years (or 10 yrs before youngest FDR dx) | Every 5 years | Genetic counselling referral |
| Lynch syndrome | Colonoscopy | 25 years (or 10 yrs before youngest family dx) | Every 1–2 years | Genetic counselling; consider aspirin chemoprevention |
| FAP | Flexible sigmoidoscopy / colonoscopy | 12–15 years | Every 1–2 years | Genetic testing; prophylactic colectomy discussion |
| IBD (extensive colitis >8 yrs) | Surveillance colonoscopy with chromoendoscopy | 8 years after symptom onset | Every 1–3 years (risk-dependent) | Pancolonic dye-spray or virtual chromoendoscopy preferred |
Primary Care Implementation
General practitioners (GPs) are the cornerstone of CRC screening in Australia. Primary care clinicians are responsible for opportunistic screening discussions, supporting NBCSP participation, assessing risk, initiating appropriate referrals, and managing surveillance recall.
When to Start Screening
1
Age 45 — Initiate Discussion
Per the USPSTF 2021 update and American Cancer Society guidelines, CRC screening should be offered from age 45 for average-risk individuals. In Australia, the NBCSP begins at age 50, but GPs may initiate screening discussions at 45, particularly for patients with minor risk factors or patient preference. FIT is a reasonable starting modality.
2
Age 50 — NBCSP Eligible
All asymptomatic Australians aged 50–74 should be actively encouraged to participate in the NBCSP. GPs should confirm that patients have received and returned their FIT kit. Non-responders should be followed up at subsequent consultations.
3
Earlier — If Risk Factors Present
Family history assessment should occur at any age presentation. Patients with FDRs with CRC, personal history of adenomas, IBD, or symptoms warrant earlier investigation. Do not delay colonoscopy referral for symptomatic patients based on age.
Family History Assessment — The 3-Question Screen
Every adult presenting for a health check or aged 45+ should be asked:
- Has any first-degree relative (parent, sibling, child) been diagnosed with colorectal cancer?
- If yes, how old were they at diagnosis? (Before or after 55 years?)
- Is there a known hereditary cancer syndrome in the family (e.g., Lynch syndrome, FAP)?
Opportunistic Screening Strategies in General Practice
- Health assessments: Incorporate CRC screening into 45–49-year-old health checks, 75+ health assessments, and Aboriginal and Torres Strait Islander health checks (MBS item 715).
- Chronic disease consultations: Use diabetes, cardiovascular, or other chronic disease reviews as an opportunity to discuss CRC screening status.
- Practice registers and recalls: Maintain a register of patients aged 50–74 and their screening status. Use clinical software (e.g., Best Practice, Medical Director) to set reminders for overdue screening.
- Patient education: Provide written resources (Cancer Council Australia pamphlets) and explain the purpose, simplicity, and importance of the FIT kit.
- Address barriers: Common reasons for non-participation include embarrassment, lack of awareness, perceived low risk, and forgetting. Direct GP endorsement significantly improves uptake.
GP endorsement matters: Evidence consistently shows that a direct recommendation from a GP is one of the strongest predictors of NBCSP kit completion. A brief verbal statement — "This test can prevent bowel cancer — please do it" — can improve participation by up to 20%.
MBS Items Relevant to CRC Screening in Primary Care
| MBS Item | Description | Relevance |
|---|---|---|
| 715 | Aboriginal and Torres Strait Islander health check | Opportunity to assess CRC screening status and risk |
| 699 | GP Management Plan (GPMP) | Incorporate screening recall into chronic disease management |
| 10997 | GP consultation (Level C — extended) | For detailed family history assessment and risk counselling |
| 66766 | Faecal occult blood test (FIT) | If ordering FIT outside NBCSP (symptomatic patients) |
Comorbidities and Life Expectancy Considerations
Screening decisions in older adults (≥75 years) and those with significant comorbidities should be individualised based on life expectancy, functional status, and patient preference. Screening is unlikely to benefit patients with a life expectancy of less than 10 years, as the natural history of the adenoma-carcinoma sequence means the harms of screening and colonoscopy may outweigh benefits. Conversely, healthy older adults may continue to benefit from screening.
Symptomatic patients are NOT screening: Any patient with rectal bleeding, unexplained iron deficiency anaemia, change in bowel habit, abdominal mass, or unexplained weight loss requires urgent diagnostic investigation — not screening FIT. These patients should be referred for colonoscopy directly. A negative FIT does NOT exclude CRC in symptomatic patients.
Follow-Up of Positive Tests
A positive non-invasive screening test (FIT, stool DNA) is not a diagnosis of cancer but indicates the need for definitive investigation with colonoscopy. Timely follow-up is critical — delays of more than 6 months are associated with more advanced-stage cancer at diagnosis.
Pathway After Positive FIT
1
Result Communication
The NBCSP sends positive results to both the patient and their nominated GP. GPs should proactively contact the patient to explain the result, emphasise that a positive FIT does not mean cancer, and arrange urgent colonoscopy referral.
2
Colonoscopy Referral
Referral to a GESA-accredited colonoscopist should occur promptly. Target: colonoscopy within 30 days of positive FIT result. Provide the colonoscopist with the FIT result, patient medical history, anticoagulant/antiplatelet use, and comorbidities.
3
Pre-Procedure Optimisation
Advise patients on bowel preparation. Anticoagulants (warfarin, DOACs) and antiplatelet agents (clopidogrel, ticagrelor) require proceduralist-guided management — typically stop clopidogrel 7 days prior, warfarin 5 days prior (bridging may be needed for high thrombotic risk), and DOACs 48 hours prior.
4
Results Review & Surveillance Planning
Review colonoscopy and histology results. Determine next surveillance interval based on findings (see post-polypectomy surveillance below). Communicate clearly with the patient and set recall.
Positive FIT — Expected Findings at Colonoscopy
| Finding | Approximate Proportion | Action |
|---|---|---|
| CRC confirmed | ~7–8% | Staging (CT chest/abdomen/pelvis); MDT referral; surgical/oncology |
| Advanced adenoma (≥10 mm, villous, high-grade dysplasia) | ~30–35% | Polypectomy; surveillance colonoscopy in 3 years |
| Non-advanced adenoma (<10 mm, tubular) | ~25–30% | Polypectomy; surveillance colonoscopy in 5 years |
| No significant pathology | ~25–30% | Return to NBCSP (biennial FIT); consider upper GI source if anaemia |
Post-Polypectomy Surveillance
Surveillance colonoscopy intervals should be determined by the highest-risk finding at index colonoscopy, in accordance with the 2020 Australian Colorectal Cancer Screening Guidelines and Cancer Council Australia recommendations.
| Index Colonoscopy Finding | Surveillance Interval | Notes |
|---|---|---|
| Normal or hyperplastic polyps only | No surveillance needed; return to NBCSP | FIT every 2 years per NBCSP |
| 1–2 small (<10 mm) tubular adenomas, no villous features | 5 years | Low-risk adenoma |
| 3–4 small tubular adenomas | 3 years | Intermediate risk |
| ≥5 adenomas, or any adenoma ≥10 mm, or villous features, or high-grade dysplasia | 3 years (or 1 year if ≥10 adenomas) | High-risk adenoma; consider 1 year if very high adenoma burden |
| Sessile serrated lesions (SSL) ≥10 mm or with dysplasia | 3 years | Serrated polyposis syndrome → annual colonoscopy |
| CRC resected | 1 year post-surgery, then per protocol | CEA monitoring; CT surveillance per MDT |
Tracking and Communication
- Practice systems: Use clinical software flags and recall systems to track all patients with positive FIT results. Every positive FIT should have a documented outcome — colonoscopy booked, completed, or patient declined (with documented counselling).
- Completion rates: Nationally, approximately 60–70% of patients with a positive NBCSP FIT complete follow-up colonoscopy. GPs play a crucial role in closing this gap by contacting patients directly and addressing barriers (cost, transport, anxiety, language).
- Patient communication: Provide clear, written follow-up instructions. Use interpreter services where needed. Emphasise that most positive FIT results do NOT indicate cancer.
- Medicare Safety Net: Patients may incur out-of-pocket costs for colonoscopy in private settings. Discuss the option of public hospital waitlist or identify bulk-billing colonoscopists where available.
Critical safety net: Never assume a positive FIT is a false positive without colonoscopy. A negative colonoscopy in the setting of positive FIT should prompt consideration of upper GI bleeding source, particularly in patients with iron deficiency anaemia.
Investigations
Investigations in CRC screening encompass the screening tests themselves and the diagnostic workup triggered by positive results or symptoms.
Essential
Faecal Immunochemical Test (FIT)
Quantitative immunoassay for human haemoglobin. NBCSP provides kits free of charge. MBS item 66766 for private requests. Single sample; no dietary restrictions required.
Essential
Colonoscopy with Biopsy/Polypectomy
MBS item 32222. GESA-accredited colonoscopist. Full bowel preparation required. Caecal intubation rate >95% quality benchmark. Histopathology of all excised lesions.
Available
Full Blood Count & Iron Studies
Iron deficiency anaemia (low ferritin, low transferrin saturation, high TIBC) in the absence of obvious cause mandates colonic investigation. MBS item 65070 (FBC), 66555 (iron studies).
Available
Flexible Sigmoidoscopy
MBS item 32218. Limited bowel preparation (enema only). Can be performed without sedation. Examines distal colon only — misses proximal lesions.
Available
CT Colonography
MBS item 57721 (specialist request). Requires bowel preparation (gas insufflation). Sensitivity >90% for polyps ≥10 mm. Does not enable biopsy/polypectomy — positive findings require subsequent colonoscopy.
Referral
Molecular Tumour Testing (MSI/MMR)
Microsatellite instability (MSI) and mismatch repair (MMR) protein testing (immunohistochemistry for MLH1, MSH2, MSH6, PMS2) on all CRC specimens. Identifies Lynch syndrome candidates and guides immunotherapy eligibility. Available at all major pathology laboratories.
Referral
Germline Genetic Testing
For patients with MSI-high tumours, Amsterdam/Bethesda criteria, or suggestive family history. Medicare-funded through clinical genetics services. Cascade testing for at-risk family members.
Specialist
Stool DNA (Cologuard®)
Not PBS/MBS funded in Australia. Private pathology may offer at ~0–400 AUD out-of-pocket. Consider when colonoscopy declined/contraindicated. Higher false-positive rate than FIT.
CRC Staging Investigations (for confirmed CRC)
Once CRC is confirmed histologically, staging is coordinated by the treating surgical or oncology team:
- CT chest/abdomen/pelvis with IV contrast: Standard staging imaging. MBS item 55054.
- Pelvic MRI: Essential for rectal cancer local staging (T and N staging, circumferential resection margin assessment). MBS item 63054.
- Carcinoembryonic antigen (CEA): Baseline serum CEA for post-treatment surveillance. MBS item 66398.
- PET-CT: Not routine; considered for equivocal findings on CT or suspected recurrence. MBS item 61605 (specialist request).
Special Populations
Pregnancy
Screening: Routine CRC screening is not indicated during pregnancy. NBCSP kits should be deferred to the postpartum period.
Symptomatic patients: Rectal bleeding in pregnancy is most commonly haemorrhoidal, but persistent or unexplained bleeding warrants investigation. Flexible sigmoidoscopy without sedation is considered safe in pregnancy.
Colonoscopy: Can be performed in the second trimester if clinically indicated, with appropriate obstetric and anaesthetic support. Avoid in the first trimester if possible.
Known CRC in pregnancy: Managed by multidisciplinary team including obstetrics, surgery, oncology, and neonatology. Treatment timing depends on gestational age and cancer stage.
Paediatrics & Young Adults
CRC in paediatrics: Extremely rare in children; CRC in those <30 years should raise suspicion for hereditary syndromes (FAP, Lynch, constitutional mismatch repair deficiency).
FAP surveillance: Genetic testing at age 12–14 if family mutation known. Flexible sigmoidoscopy from age 12–15 annually; prophylactic colectomy typically by late teens/early adulthood.
Lynch syndrome: Colonoscopy from age 25 (or 10 years before youngest family cancer diagnosis), every 1–2 years.
Rising incidence: Epidemiological data suggest increasing CRC incidence in adults aged 30–49 internationally; Australian data support this trend. Clinicians should maintain a low threshold for investigating symptoms in younger adults.
Elderly (≥75 years)
Individualised approach: The NBCSP extends to age 74. Beyond 75, screening decisions should consider life expectancy (≥10 years for net benefit), functional status, and comorbidity burden.
Bowel preparation risks: Dehydration, electrolyte disturbance, and renal impairment are more common in the elderly with bowel preparation. Use lower-volume preparations and ensure adequate hydration support.
Colonoscopy risk: Perforation and cardiopulmonary complications increase with age. Shared decision-making is essential.
Competing mortality: In frail elderly, competing causes of death may outweigh the benefit of CRC detection. Avoid over-investigation.
Renal Impairment
Bowel preparation caution: Sodium phosphate–based preparations are CONTRAINDICATED in CKD (eGFR <30 mL/min/1.73 m²) due to risk of fatal hyperphosphataemia. Use polyethylene glycol (PEG)-based preparations (e.g., Movicol®, Glycoprep®).
Dialysis patients: Coordinate colonoscopy scheduling with dialysis. Ensure adequate fluid management and electrolyte monitoring peri-procedure.
FIT validity: FIT remains valid in CKD; renal disease does not affect faecal haemoglobin interpretation.
Hepatic Impairment
Coagulopathy: Patients with cirrhosis and coagulopathy (INR >1.5, platelets <50 × 10⁹/L) require haematology input before polypectomy. Low-dose aspirin may be continued; dual antiplatelet therapy and anticoagulants require proceduralist guidance.
Portal hypertension: Colonic varices are rare but may cause false-positive FIT or confound colonoscopy findings.
Sedation: Increased sensitivity to sedative agents in hepatic impairment. Consider anaesthetist-administered sedation for advanced liver disease.
Immunocompromised
IBD patients: Long-standing extensive colitis (>8 years) confers increased CRC risk. Surveillance colonoscopy with chromoendoscopy (dye-spray or virtual) is recommended every 1–3 years depending on risk factors (concurrent PSC, family history, severity of inflammation).
Transplant recipients: Solid organ transplant recipients have modestly increased CRC risk. Follow general population screening guidelines but consider earlier initiation.
HIV: CRC screening follows general population guidelines; no evidence for increased CRC risk specifically in HIV. However, maintain vigilance for symptoms.
Aboriginal and Torres Strait Islander Health Considerations
Aboriginal and Torres Strait Islander Health
Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of colorectal cancer. While CRC incidence rates are broadly similar to or slightly lower than the non-Indigenous population, mortality rates are significantly higher — estimated at 1.5 to 2 times the non-Indigenous rate. This disparity reflects later-stage diagnosis, lower screening participation, reduced access to timely colonoscopy and specialist services, and the compounding effects of social determinants of health.
Strengths-based approach: Community-controlled health services (ACCHSs) have demonstrated superior screening outcomes through culturally embedded, holistic care models. Supporting and resourcing ACCHSs to lead CRC screening initiatives is a key strategy for closing the gap. Telehealth consultations with gastroenterologists can facilitate timely specialist input in remote settings.
📚 References
- 1. Australian Institute of Health and Welfare. Bowel cancer screening in Australia: monitoring report. Canberra: AIHW; 2023.
- 2. Cancer Council Australia Colorectal Cancer Guidelines Working Party. Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. Sydney: Cancer Council Australia; 2017 (updated 2020).
- 3. > US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965–1977.
- 4. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250–281.
- 5. > Atkin W, Wooldrage K, Parkin DM, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet. 2017;389(10076):1299–1311.
- 6. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287–1297.
- 7. Gastroenterological Society of Australia. Colonoscopy clinical care standards. Melbourne: GESA; 2020.
- 8. Australian Government Department of Health and Aged Care. National Bowel Cancer Screening Program. Canberra: DoH; 2024. Available from: https://www.health.gov.au/our-work/national-bowel-cancer-screening-program.
- 9. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008;103(6):1541–1549.
- 10. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153(1):307–323.
- 11. Cunningham M, Rumbold AR, Zhang X, Condon JR. Incidence, aetiology, and outcomes of cancer in Indigenous peoples in Australia. Lancet Oncol. 2008;9(6):585–595.
- 12. National Health and Medical Research Council. Clinical practice guidelines for the management of colorectal cancer. 2nd ed. Canberra: NHMRC; 2005 (superseded by Cancer Council guidelines; retained for historical context).
- 13. Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology. 2008;135(6):1899–1906.
- 14. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med. 1993;329(27):1977–1981.